Nicholas Runcie

@nicholasruncie.bsky.social

AI for drug design | Oxford DPhil student | MChem | RSci | opinions my own

🚀 LLMs can now do chemistry! Our new preprint shows that state-of-the-art reasoning models can now perform advanced chemical reasoning tasks, without any assistance from external tools. Here’s what o3-mini can already do👇 (1/🧵)

Bild

We're excited to announce we've raised a Seed round with Dimension, Amplify, NVIDIA NVentures, and Compound! Read more about our mission at achira.ai

Andrew Dunn@andrewedunn.bsky.social · last yr.

NEW: Achira has launched with a $33M seed round I talked with CEO @jchodera.bsky.social about plans to combine AI- and physics-based methods for drug discovery and moving beyond 45 years of the same type of models behind molecular dynamics. My latest @endpts.com: endpts.com/achira-raise...

It’s an exciting time in protein design! 🧬✨ But much of the therapeutic potential—especially for antibodies—remains untapped. Why? 🤔 Antibodies seem like ideal candidates for design! 💉 Here’s a quick thread summarising our new review paper on the state of antibody structure prediction. 👇 1/

Challenges and compromises: Predicting unbound antibody structures with deep learning

Therapeutic antibodies are manufactured, stored and administered in the free state; this makes understanding the unbound form key to designing and imp…

sciencedirect.com